维他命的坚持和事故的风险:一个警告故事
Colin R Dormuth1, Amanda R Patrick, William H Shrank
1Therapeutics Initiative, and Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Victoria, BC, Canada. colin.dormuth@ti.ubc.ca
Circulation
|April 8, 2009
概括
坚持使用他类药物治疗的患者更健康,更健康,不一定受到药物本身的保护. 这凸显了预防性药物研究中的潜在偏见.
科学领域:
- 心血管医学 心血管医学
- 药理流行病学 药理流行病学
- 医疗服务研究 医疗服务研究
背景情况:
- 预防性药物研究的风险偏差来自更健康的患者坚持更多的药物.
- 研究是否对他类药物的坚持与不受他类药物的影响的结果相关,如意外.
研究的目的:
- 通过检查与非因果结果的关联来评估他类药物研究中的偏见.
- 为了确定是否对他类药物的坚持反映了更健康的行为,而不是药物的有效性.
主要方法:
- 在不列颠哥伦比亚省对141,086名用于初级预防的他类药物发起者的前性队列研究.
- 使用多变量调整的考克斯比例危险模型来分析依从性和结果.
- 检查了他类药物坚持与事故,查和其他疾病之间的关联.
主要成果:
- 较高的他类药物坚持与较低的机动车辆事故率 (HR 0.75) 和工作场所事故率 (HR 0.77) 有关.
- 附加患者显示查服务利用率增加 (HR 1.17).
- 坚持与发展无关疾病的可能性较低相关 (HR 0.87).
结论:
- 斯坦丁坚持与更健康的追求有关,表明行为效应而不是纯粹的药理效应.
- 调查结果表明,由于坚持偏差,在解释仅归因于预防性药物的保护作用时要谨慎.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Drug Toxicity: Risk factors
248
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
248
Drug toxicity: Drug–Drug Interaction
437
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
437
Coronary Artery Disease V: Interprofessional Care
450
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
450
Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747


